Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Thursday, July 18, 2024 | Back issues
Courthouse News Service Courthouse News Service

Pharmaceutical Antitrust

A federal judge in Connecticut granted class certification and preliminary approval of a $54 million proposed settlement in an antitrust case claiming drug makers blocked generic alternatives to the stroke medication Aggrenox.

BRIDGEPORT, Conn. – A federal judge in Connecticut granted class certification and preliminary approval of a $54 million proposed settlement in an antitrust case claiming drug makers blocked generic alternatives to the stroke medication Aggrenox.

Categories / Business, Health

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...